JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Promising results after vacuum-assisted wound closure and mesh-mediated fascial traction.

Danish Medical Journal 2012 September
INTRODUCTION: Patients with an open abdomen (OA) present a major challenge to the surgeon. High mortality and associated complication rates have been reported depending on the specific method of temporary abdominal closure, the primary disorder and any co-morbidity. Vacuum-assisted wound closure and mesh-mediated fascial traction (VAWCM) is a novel technique recently introduced for late fascial closure of the OA. In previous studies, the disease aetiologies were mainly vascular and visceral surgical disease and trauma. We report our results using VAWCM in a non-trauma patient population treated with an OA due to visceral surgical disease.

MATERIAL AND METHODS: Medical records of all patients in our department treated with VAWCM during the period from 1 August 2009 to 31 May 2011 were reviewed. All sixteen patients were non-trauma patients. The initial treatment was vacuum-assisted closure (VAC) (Abdominal Dressing System KCI, San Antonio, Texas, USA). VAWCM treatment was initiated if complete fascial closure could not be obtained with VAC.

RESULTS: Two patients died of multiple organ failure that was not associated with the VAWCM treatment. In one patient, treatment was terminated due to a very short life expectancy. We achieved a complete fascial closure rate in seven out of 16 patients. One patient had a pancreatic fistula at discharge that was not associated with the VAWCM treatment. No enteric fistulas occurred.

CONCLUSION: It seems that VAWCM can improve the rate of complete fascial closure after treatment with OA without increasing the mortality or the occurrence of enteric fistula compared with other kinds of temporary abdominal closure.

FUNDING: not relevant.

TRIAL REGISTRATION: not relevant.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app